Quick summary
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide that promotes delta-wave deep sleep without sedation or dependency risks. First isolated from rabbit brain in 1977, it also modulates stress tolerance and pain perception.
Overview
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide first isolated from rabbit brain in 1977. It is named for its ability to induce delta-wave (deep) sleep in animal models. Beyond sleep, it has demonstrated effects on stress tolerance, pain modulation, and endocrine regulation. It is used in the biohacking community for improving sleep architecture and recovery.
Mechanism of action
DSIP modulates multiple neurotransmitter systems including GABAergic, glutamatergic, and serotonergic pathways. It promotes the release of luteinizing hormone (LH) while limiting somatostatin secretion, and modulates corticotropin activity, contributing to stress reduction. It appears to act as a sleep-promoting substance by enhancing slow-wave (delta) sleep without the sedation or dependency risks of benzodiazepines or Z-drugs.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| sleep improvement | subcutaneous | 100–300 mcg | daily before bed | Inject 30-60 minutes before desired sleep time. Cycles of 2-4 weeks. Some users report best results with intermittent use. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Initial studies by Schoenenberger & Monnier (1977) demonstrated delta-wave sleep induction in rabbits. Subsequent human studies showed improvements in sleep quality, reduced sleep latency, and increased time in deep sleep stages. Studies in chronic insomnia patients showed normalized sleep patterns. Also shown to reduce alcohol and opioid withdrawal symptoms in clinical observations. Research is limited but promising; no large-scale controlled trials in Western literature.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with DSIP for synergistic effects.
Legal status
Not FDA-approved. Available as a research peptide. Not scheduled or banned. Limited regulatory attention due to niche use.
Sourcing & access
Research compound
DSIP is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
DSIP (Delta Sleep-Inducing Peptide) is a neuropeptide first isolated from rabbit brain in 1977 by researchers studying thalamic delta-wave sleep induction. It is a nonapeptide (nine amino acids) that modulates sleep architecture and is found endogenously in the hypothalamus, limbic system, pituitary, and peripheral tissues. Its concentrations show circadian variation correlated with sleep-wake cycles.
DSIP modulates sleep through multiple neurotransmitter systems, including GABAergic, glutamatergic, and serotonergic pathways, without acting as a direct sedative. Unlike benzodiazepines or z-drugs, it does not cause sedation, respiratory depression, or dependency. It appears to shift the balance toward restorative delta-wave sleep rather than simply inducing unconsciousness, making it mechanistically distinct from conventional sleep medications.
Typical research protocols use 100 to 300 micrograms administered subcutaneously 30 to 60 minutes before the intended sleep period. Cycle lengths of 2 to 4 weeks are commonly used in practice. All dosing information is derived from limited human trials and self-experimentation reports, not from large-scale clinical studies. No FDA-approved dosing protocol exists.
No evidence of addiction, dependence, or withdrawal has been reported in the published literature on DSIP. This distinguishes it mechanistically from habit-forming sleep medications such as benzodiazepines and non-benzodiazepine hypnotics, which act on GABA-A receptors and carry established dependence risk. DSIP's modulatory mechanism does not involve the reward pathways associated with addictive compounds.
The most commonly reported side effects are morning grogginess, headache, and injection site reactions at the administration site. Some users report unusually vivid or intense dreams, consistent with DSIP's effects on delta-wave sleep architecture. Serious adverse events have not been documented in the available literature, though the evidence base consists primarily of small trials and anecdotal reports rather than large safety studies.
Research references
- The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptidePubMed
- The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleepPubMed
- Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacsPubMed
- Delta sleep-inducing peptide (DSIP): a still unresolved riddlePubMed
- Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot studyPubMed